Guardant Health GH Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Total Revenue by Product | ||||||
| Biopharma and data | $52.98M-1.9% | $54.01M-1.3% | $54.73M-2.3% | $56.02M+23.5% | $45.38M-8.4% | |
| Licensing and other | $2.14M-1.8% | $2.18M+11.9% | $1.95M-24.1% | $2.57M+38.2% | $1.86M-27.6% | |
| Oncology | $204.95M+7.9% | $189.95M+3.0% | $184.4M+16.2% | $158.69M+5.4% | $150.56M+3.4% | |
| Screening | $41.59M+18.4% | $35.13M+45.7% | $24.11M+62.8% | $14.81M+161% | $5.68M+37.8% | |
| Revenue by Geography | ||||||
| International | $17.04M-3.9% | $17.72M+12.5% | $15.76M+2.3% | $15.4M+56.2% | $9.86M-3.5% | |
| United States | $284.63M+8.0% | $263.55M+5.7% | $249.44M+15.1% | $216.68M+11.9% | $193.61M+1.1% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Guardant Health break its business down?
- Guardant Health (GH) reports total revenue by product across 4 parts — Biopharma and data, Licensing and other, Oncology and Screening. Each is extracted from the segment footnotes and tracked over time.
- Where does Guardant Health's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Guardant Health's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
